BRG1/SMARCA4 CUTANA™ CUT&RUN Antibody

(Click to enlarge)

Figure 2: BRG1 CUT&RUN peak enrichment and functional overlap
The CUT&RUN data from Figure 1 was subjected to peak calling using MACS2. BRG1 peaks overlapped with BRD4 antibody CUT&RUN peaks (EpiCypher 13-2003, top), as has been demonstrated in the literature (Conrad et al., 2017). Three representative loci show BRG1 peaks in relation to control and BRD4 antibodies (bottom, Integrative Genomics Viewer).

(Click to enlarge)

Figure 3: Western blot detection of human BRG1.
Whole cell lysates were isolated from HeLa, HEK293T (”293T”), and Jurkat cells using NETN lysis buffer. Lysates (15 µg) were loaded onto 4-8% SDS-PAGE gel and analyzed under standard western blot conditions using BRG1 antibody (0.1 µg/mL).

(Click to enlarge)

Figure 4: Western blot detection of mouse BRG1
Whole cell lysates were isolated from NIH 3T3 (“3T3”) cells using NETN lysis buffer. Lysates (15 µg) were loaded onto 4-8% SDS-PAGE gel and analyzed under standard western blot conditions using BRG1 antibody (0.1 µg/mL).

(Click to enlarge)

Figure 5: Immunoprecipitation of human BRG1
EpiCypher BRG1 antibody (3 µg) was used to immunoprecipitate whole cell lysates isolated from HeLa cells using NETN lysis buffer (1 mg per IP). A negative control IgG antibody and positive control antibody to a different BRG1/SMARCA4 epitope (Bethyl Laboratories) were also used to demonstrate specificity of the IP. Immunoprecipitates were loaded onto 4-20% SDS-PAGE gel (20% of IP loaded) and probed via western blot with EpiCypher BRG1 antibody (1 µg/mL).

(Click to enlarge)

Figure 6: Immunohistochemistry detection of human and mouse BRG1
(A) FFPE section of human ovarian carcinoma examined using BRG1 antibody (1:1,000 dilution, 0.2 µg/mL). (B) FFPE section of mouse renal cell carcinoma examined using BRG1 antibody (1:1,000 dilution, 0.2 µg/mL).